WYOMING MEDICAID
Preferred Drug List (PDL) - September 29, 2017

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.

Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population, as well as the adult population for those plans where PA/PDL limits are allowed.

Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the GHS PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES PLEASE CONTACT GHS FOR QUESTIONS
ADDICTION	**BUPRENORPHINE COMBINATIONS**	SUBOXONE FILM	Client must have a diagnosis of opioid dependence or abuse. This is not to be used for the treatment of chronic pain. Prescriber must have a XDEA number. Prior authorization will be required before any narcotic, benzodiazepine, or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills. Oral buprenorphine will be approved for clients that are pregnant or nursing or with a documented allergy to naloxone. Please submit PA requests on the "Oral Buprenorphine/Naloxone or Oral Buprenorphine" PA form available at www.wymedicaid.org. Dosage limits apply During first two years of treatment: 16mg After two years of treatment: 8mg	BUNAVAIL buprenorphine (oral) buprenorphine/naloxone tablets (use preferred) ZUBSOLV
	NALTREXONE	naltrexone VIVITROL	Client must have a diagnosis of alcohol or opioid dependance. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills.	
ALLERGY / ASTHMA	**ANTIHISTAMINES, MINIMALLY SEDATING**	cetirizine fexofenadine loratadine	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	desloratadine CLARINEX RDT/SYRUP levocetirizine
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS	cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX-D
	ANTICHOLINERGIC BRONCHODILATORS	ipratropium SPIRIVA HANDIHALER	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Spiriva 5 day STARTER package will be allowed one (1) time per recipient.	ATROVENT HFA INCRUSE ELLIPTA SPIRIVA RESPIMAT *(use preferred agent)* TUDORZA
	INHALED COMBINATION AGENTS	ADVAIR DISK/HFA COMBIVENT DULERA SYMBICORT	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. **Will also require the diagnosis of COPD. ***Will also require the diagnosis of COPD or uncontrolled asthma. Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.	AIRDUO ANORO ELLIPTA** BREO ELLIPTA*** STIOLTO
	LEUKOTRIENE MODIFIERS	montelukast	Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	zafirlukast ZYFLO
	LONG ACTING BRONCHODILATORS	BROVANA FORADIL SEREVENT	Trial and failure of two (2) preferred agents greater than or equal to 30 days int the last 12 months will be required before approval can be given for a non-preferred agent.	PERFOROMIST STRIVERDI
	NASAL ANTIHISTAMINES	**ASTELIN** azelastine 0.1%	Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.	azelastine 0.15% AZENASE *(use separate agents)* DYMISTA *(use separate agents)* olopatadine 0.6%
	NASAL STEROIDS	BECONASE AQ flunisolide fluticasone **NASONEX***	Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Budesonide will be approved for pregnancy.	AZENASE *(use separate agents)* budesonide DYMISTA *(use separate agents)* OMNARIS QNASL TICANASE *(use separate agents)* triamcinolone VERAMYST ZETONNA
	SHORT ACTING BRONCHODILATORS - INHALERS	PROAIR HFA PROVENTIL HFA VENTOLIN HFA	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Minimum day supply of at 16 days is required	PROAIR RESPICLICK XOPENEX HFA

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT GHS FOR QUESTIONS
ALLERGY / ASTHMA continued	**SHORT ACTING BRONCHODILATORS - NEBULIZERS**		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	
	albuterol neb levalbuterol neb			
	STEROID INHALANTS		Trial and failure of three (3) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alvesco will be approved for a history of oral thrush with steroid inhalants.	AEROBID/AEROBID-M AEROSPAN ALVESCO ARMONAIR ARNUITY ASMANEX budesonide susp 0.25mg/2ml AND 0.5mg/2ml (BRAND IS PREFERRED) budesonide susp 1mg/2ml QVAR
	FLOVENT HFA/DISK **PULMICORT SUSP 0.25mg/2ml AND 0.5mg/2ml*** PULMICORT FLEXHALER			
	EPINEPHRINE			ADRENACLICK *(use preferred agent)* AUVI-Q *(use preferred agent)* EPI-PEN *(use preferred agent)*
	epinephrine auto-injector pen			
ARTHRITIS	**IMMUNOMODULATORS**			
	ANKYLOSING SPONDYLITIS (AS)		Client must have diagnosis of AS prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of AS and a 56-day trial and failure of both preferred agents. Quantity Limits apply for all diagnoses: Enbrel 25mg - limited to 10 per month Enbrel 50mg - limited to 5 per month Humira 20mg - limited to 10 per month Humira 40mg - limited to 5 per month	CIMZIA COSENTYX REMICADE SIMPONI
		ENBREL HUMIRA		
	JUVENILE IDIOPATHIC ARTHRITIS (JIA)		Client must have diagnosis of JIA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of JIA and a 56-day trial and failure of both preferred agents.	ACTEMRA ORENCIA
		ENBREL HUMIRA		
	PSORIATIC ARTHRITIS (PA)		Client must have diagnosis of PA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of PA and a 56-day trial and failure of both preferred agents.	CIMZIA COSENTYX OTEZLA REMICADE SIMPONI
		ENBREL HUMIRA		
	RHEUMATOID ARTHRITIS (RA)		Client must have diagnosis of RA and a 56-day trial and failure of methotrexate prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of RA and a 56-day trial and failure of both preferred agents.	ACTEMRA CIMZIA KINERET ORENCIA REMICADE RITUXAN SIMPONI XELJANZ/XR
		ENBREL HUMIRA		
CONVULSIONS	**DIAZEPAM RECTAL GEL**			diazepam gel (BRAND IS PREFERRED)
	DIASTAT*			
	ORAL ANTICONVULSANTS		Limited to FDA approved indications	
		APTIOM FYCOMPA VIMPAT		
CROHN'S	**IMMUNOMODULATORS**		Client must have diagnosis of Crohn's prior to approval of the preferred agent. To receive a non-preferred agent, client must have a diagnosis of Crohn's and a 56-day trial and failure of the preferred agent.	CIMZIA REMICADE TYSABRI *(additional criteria applies)*
		HUMIRA		
DERMATOLOGY	**IMPETIGO ANTIBIOTICS**		Trial and failure of ALL preferred agents greater than or equal to 7 days in the past 90 days. Use smallest size appropriate for 7 day trial.	
	gentamicin mupirocin			
	BENZOYL PEROXIDE/CLINDAMYCIN COMBOs		Clients must be 12 to 20 years of age and have a diagnosis of acne vulgaris. Requires prior authorization for clients less than 12 years of age. Acne combinations are limited to clients under the age of 21.	ACANYA benzoyl peroxide/clindamycin (BRAND IS PREFERRED)
		BENZACLIN* clindamycyin/benzoyl peroxide 1.2 (1)-5% (Refrig)		
	CORTICOSTEROIDS - STEP 1 AGENTS **C=CREAM; G=GEL; L=LOTION; O=OINTMENT**		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	PANDEL prednicarbate 0.1% (C,O) TEXACORT 2.5% (S)
	LOW POTENCY			
	alclometasone desonide DESOWEN 0.05% (L) fluocinolone 0.01% hydrocortisone butyrate 0.1% (C) hydrocortisone 1%, 2.5% (C,L,O) SYNALAR 0.01%			
	MEDIUM POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	Clocortolone Pivalate CORDRAN/SP fluticasone 0.05% (L) hydrocortisone butyrate 0.1% (O) TOPICORT LP TRIANEX
	betamethasone valerate CUTIVATE 0.05% (C) DERMATOP 0.1% (C) desoximetasone 0.05% (C) ELOCON 0.1% fluocinolone 0.025% fluticasone 0.05% (C) hydrocortisone probutate 0.1% (C) mometasone SYNALAR 0.025% TOPICORT 0.05% (C) triamcinolone 0.025%, 0.1%			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT GHS FOR QUESTIONS
DERMATOLOGY continued	**HIGH POTENCY**		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	APEXICON amcinonide 0.1% (C,L,O) augmented betamethasone 0.05% (G,L,O) clobetasol 0.05% (L) desoximetasone 0.05%, 0.25% (C,G,O) fluocinonide 0.1% (C) HALOG
	betamethasone dipropionate clobetasol/E 0.05% (C,G,O,S) diflorasone DIPROLENE 0.05% (L) fluocinonide flurandrenolide fluticasone 0.005% (O) halobetasol TEMOVATE/E TOPICORT 0.25% (C) triamcinolone 0.5% ULTRAVATE 0.05%			
	IMMUNOMODULATORS - STEP 2 AGENTS		**<u>To receive a step 2 agent:</u>** Trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial <u>and</u> a trial and failure of a preferred high potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days. For clients less than two (2) years of age, a trial and failure of a preferred low potency corticosteroid greater than or equal to a 21 day trial <u>and</u> a trial and failure of a preferred medium potency topical cortiscosteroid greater than or equal to a 21 day trial in the last 90 days.	
		ELIDEL tacrolimus ointment		
	PHOSPHODIESTERASE 4 INHIBITOR - STEP 3 AGENT		**<u>To receive a step 3 agent:</u>** Trial and failure of a preferred step 2 agent (immunomodulator) greater than or equal to a 21 day trial within the last 30 days.	DUPIXENT EUCRISA
	PLAQUE PSORIASIS (PP)		Client must have diagnosis of PP prior to approval of a step 1 agent (Enbrel or Humira). To receive the step 2 agent (Cosentyx), client must have a diagnosis of PP and a 56-day trial and failure of Humira. To receive a non-preferred agent, client must have a diagnosis of PP and a 56-day trial and failure of both preferred agents.	OTEZLA REMICADE STELARA TALTZ
	STEP 1 AGENTS			
		ENBREL HUMIRA		
	STEP 2 AGENT			
		COSENTYX		
	SALICYLIC ACID			All other topical salicylic acid formulations.
	salicylic acid cream 6% salicylic acid lotion 6% salicylic acid shampoo 6%			
	SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.	LINDANE OVIDE
	NATROBA permethrin SKLICE			
	UREA			All other topical urea formulations.
	ALUVEA CREAM 33% UMECTA EMULSION umecta mousse aerosal 40% urea lotion 40% urea lotion 45%			
DIABETES	**DIABETES AGENTS**			metformin SR 24HR osmotic release *(use preferred agent)* metformin SR 24HR modified release *(use preferred agent)* RIOMET *(use preferred agent)*
	BIGUANIDES			
	metformin/ER			
	α−GLUCOSIDASE INHIBITORS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	**GLYSET***
	acarbose			
	MEGLITINIDES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	repaglinide
	nateglinide			
	THIAZOLIDINEDIONES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACTOSPLUS MET *(use separate agents)* AVANDIA AVANDAMET *(use separate agents)*
	pioglitazone			
	SULFONYLUREAS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	glimepiride/ER glipizide/ER glyburide/ER			
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	alogliptin GLYXAMBI *(use separate preferred agents)* ONGLYZA TRADJENTA
		JANUVIA		
	DPP-4 INHIBITOR COMBO AGENTS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	alogliptin/metformin alogliptin/pioglitazone *(use separate preferred agents)* JENTADUETO JUVISYNC *(use separate preferred agents)* KOMBIGLYZE
		JANUMET/XR		
	INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent. Dosage Limits Apply: Victoza: 1.8mg/day	ADLYXIN BYDUREON SOLIQUA TANZEUM TRULICITY
		BYETTA VICTOZA		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (Generic is preferred if available. PLEASE CONTACT QHS FOR QUESTIONS)
DIABETES continued	**SGLT2 INHIBITORS**	JARDIANCE	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	FARXIGA GLYXAMBI *(use separate preferred agents)* INVOKAMET/XR*(use separate preferred agents)* INVOKANA SYNJARDY/XR *(use separate preferred agents)* XIGDUO XR *(use separate preferred agents)*
	LONG-ACTING INSULIN		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently	LANTUS OPTICLIK *(use preferred agent)* TOUJEO *(use preferred agent)* TRESIBA *(use preferred agent)* XULTOPHY *(use preferred agent)*
	LANTUS SOLOSTAR LANTUS vial LEVEMIR			
	DIABETIC METERS/TEST STRIPS		Quantity limits apply: Insulin Dependent Clients: 10 strips/day Non-Insulin Dependent Clients: 4 strips/day Clients are limited to 1 meter/365 days	ALL OTHER METERS AND TEST STRIPS
	FREESTYLE INSULINX FREESTYLE LITE FREESTYLE FREEDOM LITE ONE TOUCH ULTRA ONE TOUCH ULTRA 2 ONE TOUCH ULTRA MINI ONE TOUCH ULTRASMART ONE TOUCH VERIO ONE TOUCH VERIO FLEX PRECISION XTRA			
EAR	**ANTIBIOTIC/STEROID COMBINATION**			ciprofloxacin 0.2% *(use preferred agent)* CIPRO HC *(use preferred agent)* COLY-MYCIN S *(use preferred agent)* CORTISPORIN-TC *(use preferred agent)* FLUOCINOLONE ACET OIL 0.01% *(use preferred agent)* ofloxacin *(use preferred agent)*
	CIPRODEX Neo/Poly/HC Suspension and Solution			
FIBROMYALGIA	**FIBROMYALGIA STEP 1**			
	amitriptyline cyclobenzaprine			
	FIBROMYALGIA STEP 2	SAVELLA	Trial and failure of a Step 1 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 2 agent.	
	FIBROMYALGIA STEP 3	duloxetine LYRICA	Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 3 agent. Dosage Limits Apply: Lyrica: 600mg/day	
GASTROINTESTINAL	**DIGESTIVE ENZYMES**		Prior authorization required.	PANCREAZE pancrelipase PERTZYE TRI-PASE ULTRESA VIOKASE
	CREON ZENPEP			
	IRRITABLE BOWEL SYNDROME AGENTS	AMITIZA LINZESS	Client must have a diagnosis of chronic idiopathic constipation or Irritable Bowel Syndrome (IBS) with constipation.	
	PREGNANCY INDUCED NAUSEA/VOMITING			
	DICLEGIS			
	OPIOID-INDUCED CONSTIPATION AGENTS	AMITIZA	Client must have a diagnosis of opioid-induced constipation and a three (3) month trial and failure of a secretory agent to receive the preferred agent. To receive the non-preferred agent, client must have a diagnosis of opioid-induced constipation, a three (3) month trial and failure of a secretory agent, and a three (3) month trial and failure of the preferred agent. Movantik will be approved with a diagnosis of cancer or for clients in *Movantik will be approved for a diagnosis of cancer or for clients in hospice or palliative care.	MOVANTIK*
	PROTON PUMP INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Lansoprazole solutabs will be approved for children less than or equal to 8 years of age.	ACIPHEX SPRINKLES amox/clarith/lanso pack *(use separate agents)* DEXILANT esomeprazole 24.65mg and 49.3mg **NEXIUM*** omeprazole 20.6mg capsules *(use preferred agent)* omeprazole tablets *(use preferred agent)* omeprazole/sodium bicarbonate OMECLAMOX *(use separate agents)* PREVACID solutabs rabeprazole VIMOVO *(use separate agents)*
	lansoprazole capsules omeprazole capsules pantoprazole			
	MESALAMINE		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	APRISO ASACOL/HD CANASA DELZICOL GIAZO LIALDA ROWASA
	mesalamine enema PENTASA			
GOUT	**COLCHICINE**			colchicine *(use preferred agent)* COLCRYS *(use preferred agent)*
	MITIGARE			
	XANTHINE OXIDASE AND URAT1 INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 60 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. *Concurrent use of a preferred agent will be required with Zurampic.	ZURAMPIC*
	allopurinol ULORIC			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES Generics are preferred if available PLEASE CONTACT DHS FOR QUESTIONS
HEMATOLOGY	**LOW MOLECULAR WEIGHT HEPARIN (LMWH)**		Prior authorization will be required for the 300mg/3ml strength.	FRAGMIN *(use preferred agent)* **LOVENOX 300MG/3ML***
	enoxaparin			
	DIRECT THROMBIN INHIBITOR	PRADAXA	Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval, treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE), or for the reduction in the risk of recurrence of DVT and PE after initial therapy.	
	SELECTIVE FACTOR XA INHIBITOR	ELIQUIS XARELTO	Client must have diagnosis of non-valvular atrial fibrillation, treatment for deep vein thrombosis (DVT) prophylaxis in knee or hip replacement, treatment of DVT and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE after initial therapy.	SAVAYSA *(use preferred agent)*
	THIENOPYRIDINE DERIVATIVES		Prior authorization reuquired for clients on antiplatelet therapy greater than one (1) year.	
	clopidogrel EFFIENT ticlopidine			
	CPTP DERIVATIVES		Prior authorization is required.	BRILINTA
	PAR-1 ANTAGONIST	ZONTIVITY	Client must have diagnosis of reduction of thrombotic cardiovascular events with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Must be used in conjunction with aspirin or clopidogrel.	
HEPATITIS C	**NS5A INHIBITOR**	DAKLINZA	Limited to FDA approved indication. Prior authorization will be required prior to use of Daklinza. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
	NUCLEOTIDE ANALOG POLYMERASE INHIBITOR	SOVALDI	Limited to FDA approved indication. Prior authorization will be required prior to use of Sovaldi. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
	PROTEASE INHIBITOR	OLYSIO	Limited to FDA approved indication. Prior authorization will be required prior to use of Olysio. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
	HEP C COMBO AGENTS	EPCLUSA HARVONI MAVYRET TECHNIVIE VIEKIRA PAK/XR VOSEVI** ZEPATIER*	Limited to FDA approved indication. Prior authorization will be required prior to use of Harvoni, Technivie, Viekira Pak, or Zepatier. *Testing for the presence of virus with NS5A resistance-associated polymorphisms will be required prior to Zepatier being approved. Ribavirin will be required for any client that is positive for the above mentioned polymorphism. **Vosevi will only be approved for clients that have previously treated with an HCV regimen containing an NS5A inhibitor. An SVR12 will be required prior to approval Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
HIDRADENITIS SUPPURATIVA	**IMMUNOMODULATORS**	HUMIRA	Humira will not be covered as a first line agent for the diagnosis for hidrAdenitis suppurativa.	
HORMONES	**GROWTH HORMONE**	GENOTROPIN NORDITROPIN NUTROPIN AQ	PA is required for use outside of FDA-approved indications. Evaluation by an endocrinologist is preferred. Clinical evidence of improved growth will be required on a yearly basis to support ongoing utilization. Clinical evidence of need for growth hormone will be required for adult growth hormone deficiency and pediatric growth failure due to inadequate endogenous growth hormone. Trial and failure of two (2) preferred agents within the last 12 months will be required for the following indications: Pediatric: Growth failure due to inadequate endogenous growth hormone, Prader-Willi syndrome, children born small for gestation. Turner syndrome. Adult: Replacement for those with growth hormone deficiency.	HUMATROPE OMNITROPE SAIZEN SEROSTIM TEV-TROPIN ZORBTIVE
	PROGESTIN	MAKENA	Prior authorization is required.	
	TESTOSTERONE TOPICAL GELS	**ANDROGEL***	Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. *Other testosterone dosage form products will require a diagnosis of hypogonadism or insufficient testosterone production (not outlined on PDL).*	NATESTO NASAL GEL *(use preferred agent)* TESTIM GEL *(use preferred agent)* testosterone gel 1% (BRAND IS PREFERRED) testosterone gel 2% *(use preferred agent)* VOGELXO GEL *(use preferred agent)*

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES PRIOR AUTHORIZATION REQUIRED PLEASE CONTACT OHS FOR QUESTIONS
HORMONES continued	**ORAL CONTRACEPTIVES**			amethia/LO (BRAND IS PREFERRED) aranelle *(use preferred agent)* ashlyna (BRAND IS PREFERRED) BEYAZ *(PA required)* BREVICON *(use preferred agent)* camrese/LO (BRAND IS PREFERRED) daysee (BRAND IS PREFERRED) drospir/ethi *(use preferred agent)* estarylla tri-lo (BRAND IS PREFERRED) FALESSA KIT *(use preferred agent)* introvale *(use preferred agent)* layolis FE chewable *(PA required)* levonorgest/ethinyl estrad (91-Day) levonorgest/ethinyl estradiol (Continuous) *(use preferred agent)* levonorgest/ethinyl estradiol/LO (84-7) (BRAND IS PREFERRED) LO LOESTRIN *(PA required)* LO MINASTRIN FE *(PA required)* loryna *(use preferred agent)* MINASTRIN 24 FE CHEWABLE *(PA required)* NATAZIA *(PA required)* norgest/ethi estradiol lo (BRAND IS PREFERRED) NATAZIA *(PA required)* NECON 1/50-28 *(use preferred agent)* nikki *(use preferred agent)* noreth/ethin FE chewable *(PA required)* NORINYL 1/35 *(use preferred agent)* quasense *(use preferred agent)* QUARTETTE *(PA required)* SAFYRAL *(PA required)* tri-lo sprintec (BRAND IS PREFERRED) trinessa lo (BRAND IS PREFERRED) wymzya FE chewable (BRAND IS PREFERRED) zenchent FE chewable (BRAND IS PREFERRED)
	altavera alyacen 1-35, 7/7/7 amethyst azurette apri aubra aviane balziva bekyree blisovi 1-20 FE/24, 1.5-30 FE briellyn camila caziant chateal cyclafem 1-35, 7/7/7 cyred cryselle dasetta 1-35, 7/7/7 deblitane delyla DESOGEN deso/ethinyl estradiol elinest emoquette enpresse enskyce errin estarylla falmina FEMCON FE CHEWABLE gianvi gildagia gildess 1-20/FE/24, 1.5-30/FE heather jencycla jolessa jolivette juleber junel 1-20/FE/24, 1.5-30/FE kariva kelnor kimidess kurvelo larin 1-20/FE/24, 1.5-30/FE leena lessina levonest levonor/ethi levora lomedia 24 FE **LOSEASONIQUE*** low-ogestrel lutera lyza marlissa microgestin 1-20/FE/24, 1.5-30/FE MODICON mono-linyah mononessa myzilra NECON 0.5-35, 1-35, 7/7/7, 10/11-28 nora-be norgest/ethinyl estradiol norethindrone norlyroc noreth/ethin 1-20/FE/24 NORINYL 1/50-28 nortrel 0.5-35, 1-35, 7/7/7 ocella OGESTREL orsythia **ORTHO TRI-CYCLEN LO*** **ORTHO-NOVUM 1/35, 7/7/7*** philith pimtrea pirmella 1-35, 7/7/7 portia previfem reclipsen **SEASONIQUE*** setlakin sprintec sharobel sronyx syeda tilia FE tri-estaryll tri-legest FE tri-linyah trinessa **TRI-NORINYL*** tri-previfem tri-sprintec trivora velivet vestura vienva viorele vyfemla wera 0.5-35 YAZ zarah zenchent ZOVIA			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES Generic will be dispensed if available. PLEASE CONTACT DHS FOR QUESTIONS
HYPERLIPIDEMIA	**BILE ACID SEQUESTRANT**		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non-preferred agent.	WELCHOL
	cholestyramine/light colestipol			
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	fluvastatin/ER
	lovastatin pravastatin			
	STATINS, HIGH POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	LIVALO rosuvastatin
	atorvastatin simvastatin			
	STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 10.	amlodopine/atorvastatin (BRAND IS PREFERRED)
	CADUET* VYTORIN			
	TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ANTARA fenofibric fenofibrate 43, 50, 120, 130, and 150mg LIPOFEN omega-3-acid VASCEPA
	fenofibrate 48, 54, 67, 134, 145, 160, and 200mg gemfibrozil			
HYPERTENSION	**ACE INHIBITORS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril captopril enalapril fosinopril lisinopril moexipril perindopril quinapril ramipril trandolapril			
	ACE INHIBITORS AND DIURETICS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ moexipril/HCTZ quinapril/HCTZ			
	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)		Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.	BENICAR candesartan EDARBI eprosartan 600mg telmisartan TEVETEN 400mg
		irbesartan losartan valsartan		
	ARBs AND DIURETICS		Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.	BENICAR HCT candesartan HCTZ EDARBYCLOR telmisartan HCTZ TEVETEN HCTZ valsartan HCTZ
		irbesartan HCTZ losartan HCT		
	ALPHA-BLOCKERS			clonidine patch (BRAND IS PREFERRED) NEXICLON XR *(use preferred agent)*
	CATAPRES PATCHES* clonidine			
INFECTIOUS DISEASE	**QUINOLONES**			FACTIVE moxifloxacin NOROXIN PROQUIN
	ciprofloxacin/ER levofloxacin ofloxacin			
	DOXYCYCLINE			ADOXA *(use preferred agent)* DORYX *(use preferred agent)* ORACEA *(use preferred agent)*
	doxycycline			
	MINOCYCLINE			SOLODYN *(use preferred agent)*
	minocycline/ER			
	INHALED TOBRAMYCIN		*Tobi Podhaler requires a 28 day trial of a preferred agent, as well as 28 days off of that same preferred agent prior to approval. Minimum day supply of at 56 days is required	inhaled tobramycin *(use preferred agent)*
	BETHKIS KITABIS	TOBI PODHALER*		
	ANTI-RETROVIRALS			NORVIR solution *(use preferred agent)*
	DESCOVY EVOTAZ GENVOYA NORVIR tablets/capsules ODEFSEY PREZCOBIX			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES PLEASE CONTACT OHS FOR QUESTIONS
INFLAMMATION	**NSAIDs**		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosing and quantity limits apply for ketorolac (limit 5days/34 days; max dose 40mg/day for oral tablets).	CALDOLOR *(use preferred agent)* CAMBIA POWDER *(use preferred agent)* celecoxib diclofenac 1.5% solution *(additional criteria applies)* diclofenac 3% gel *(additional criteria applies)* fenoprofen FLECTOR *(additional criteria applies)* mefenamic acid NEOPROFEN *(use preferred agent)* SPRIX *(additional criteria applies)* TIVORBEX *(use preferred agent)* VIVLODEX *(use preferred agent)* VOLTAREN *(additional criteria applies)* ZIPSOR *(use preferred agent)* ZORVOLEX *(use preferred agent)*
	diclofenac *tablets* etodolac flurbiprofen ibuprofen indomethacin ketoprofen ketorolac meclofenamate meloxicam nabumetone naproxen oxaprozin piroxicam sulindac tolmetin			
	ORAL CORTICOSTEROIDS			CELESTONE *(use preferred agent)*
	budesonide cortisone acetate dexamethasone/intensol hydrocortisone methylprednisone prednisolone prednisone			
INSOMNIA	**NON-BENZODIAZEPINES**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 18. Rozerem is non-preferred without a history of substance abuse Prior authorization will be required when a client is taking more than one insomnia agent concurrently. Dosage limits apply: zaleplon: 30mg/day zolpidem: 15mg/day	BELSOMRA EDLUAR *(additional criteria applies)* eszopiclone INTERMEZZO *(additional criteria applies)* ROZEREM zolpidem ER ZOLPIMIST *(additional criteria applies)*
	zaleplon zolpidem			
MENTAL HEALTH	**ALZHEIMER AGENTS**		Client must have a diagnosis of dementia.	donepezil 23mg *(use preferred agent)* rivastigmine patches (BRAND IS PREFERRED) NAMENDA XR NAMZARIC *(use separate agents)*
	donepezil/ODT **EXELON PATCH*** galantamine/ER memantine tablets/solution rivastigmine capsules			
	ANTIDEPRESSANTS		Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks WITHIN THE LAST 2 YEARS will be required before approval can be given for a non-preferred agent. One of the trials of preferred agents must be in the same class (NaSS, NDRI, SSRI, or SNRI) as the requested non-preferred agent. Trazodone, buspirone, fluvoxamine, MAO inhibitors, TCA's, bupropion IR, and venlafaxine IR do not require prior authorization but **will not count** towards meeting preferred therapy requirements. Clients will not be allowed to be on more than one antidepressant, including fluvoxamine, bupropion IR, and venlafaxine IR, at one time with the exception of mirtazapine or bupropion with a SSRI or SNRI. **Duloxetine will be approved for clients with a diagnosis of osteoarthritis of the knee or chronic low back pain. ***Trintellix requires trial and failure of two preferred agents in any class Clients five (5) years of age and younger will require prior authorization before approval. Dosage limits apply: bupropion ER/SR/XL: 450mg/day citalopram < 60 years of age: 60mg/day citalopram > 60 years of age: 30mg/day escitalopram: 30mg/day fluoxetine < 18 years of age: 90mg/day fluoxetine > 18 years of age: 120mg/day mirtazapine: 67.5mg/day paroxetine IR/CR < 18 years of age: 75mg/day paroxetine IR > 18 years of age: 90mg/day paroxetine CR > 18 years of age: 112.5mg/day sertraline: 300mg/day venlafaxine ER: 337.5mg/day	
	NORADRENERGIC/SPECIFIC SEROTONERICS (NaSS)			**NaSS**
	mirtazapine 15, 30, and 45mg			mirtazapine 7.5mg and rapid dissolve tablets *(use preferred agent)*
	NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITORS (NDRI)			**NDRI**
	bupropion ER/SR/XL			APLENZIN FORFIVO XL
	SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI)			**SSRI**
	citalopram escitalopram fluoxetine capsules paroxetine IR/CR sertraline			fluoxetine tablets *(use preferred agent)* VIIBRYD
	SEROTONIN/NORPINEPHRINE REUPTAKE INHIBITORS (SNRI)			**SNRI**
	venlafaxine ER capsules			duloxetine** desvenlafaxine FETZIMA PRISTIQ venlafaxine ER tablets *(use preferred agent)*
				OTHER
				TRINTELLIX***

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES PREFERRED AGENTS MAY BE REQUIRED PLEASE CONTACT GHS FOR QUESTIONS
MENTAL HEALTH continued	**ATYPICAL ANTIPSYCHOTICS**		**Quetiapine doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the GHS Pharmacy Help Desk for an override. Clients five (5) years of age and younger will require prior authorization before approval. *Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for REXULTI or VRAYLAR. Dosage limits apply: aripiprazole <13 years of age: 23mg/day aripiprazole ≥13 years of age: 45mg/day FANAPT: 36mg/day INVEGA: 18mg/day LATUDA: 240mg/day olanzapine <13 years of age: 15mg/day olanzapine ≥13 years of age: 30mg/day quetiapine <13 years of age: 600mg/day quetiapine 13-17 years of age: 900mg/day quetiapine >17 years of age: 1200mg/day risperidone ≤ 17 years of age: 5mg/day risperidone >17 years of age: 24mg/day SAPHRIS: 30mg/day ziprasidone ≤17 years of age: 180mg/day ziprasidone >17 years of age: 300mg/day	aripiprazole ODT (BRAND IS PREFERRED) paliperidone (BRAND IS PREFERRED) REXULTI* SEROQUEL XR *(use preferred agent)* VRAYLAR*
	ABILIFY MAINTENA **ABILIFY ODT*** aripiprazole tab/solution ARISTADA FANAPT **INVEGA*** INVEGA SUSTENNA/TRINZ LATUDA olanzapine quetiapine RISPERDAL CONSTA risperidone SAPHRIS ziprasidone ZYPREXA RELPREVV			
	SPECIAL ATYPICAL ANTIPSYCHOTICS		Dosage limits apply: 1350mg/day	VERSACLOZ Suspension *(use preferred agent)*
	clozapine/ODT			
	AMPHETAMINES		Clients over the age of 17 must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below). Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue. Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 4. **Vyvanse will be approved for the diagnosis of binge-eating disorder for clients 18 years of age and older. Authorizations will be approved for 12 weeks, and further use of Vyvanse for this diagnosis will require additional documentation prior to approval. ***Only authorized generics for Concerta will be covered. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Trial and failure of two (2) preferred agents (each from a different class: methylphenidate and amphetamine) greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosage limits apply: amphetamine salts combo XR: 60mg/day amphetamine salts combo: 60mg/day amphetamine salts combo (narcolepsy): 90mg/day DAYTRANA: 45mg/9 hour patch/day dextroamphetamine: 90mg/day dextroamphetamine CR: 90mg/day dexmethylphenidate: 30mg/day FOCALIN XR < 13 years of age: 45mg/day FOCALIN XR > 13 years of age: 60mg/day methylin/methylphenidate/ER: 90mg/day VYVANSE: 105mg/day	**AMPHETAMINES** amphetamine salts combo XR (BRAND IS PREFERRED) dextroamphetamine CR capsules (BRAND IS PREFERRED) DYNAVEL VYVANSE CHEWABLES ZENZEDI 2.5 AND 7.5MG TABLETS
	LONG ACTING AMPHETAMINES			
	ADDERALL XR* ADZENYS XR ODT **DEXEDRINE CAPSULES*** VYVANSE CAPSULES**			
	IMMEDIATE RELEASE AMPHETAMINES			
	amphetamine salts combo* dextroamphetamine tablets			
	METHYLPHENIDATES			**METHYLPHENIDATES** APTENSIO XR COTEMPLA dexmethylphenidate ER (BRAND IS PREFERRED) methylphenidate ER/CR/SR capsules (METADATE CD/RITALIN LA) QUILLICHEW QUILLIVANT XR SUSPENSION
	LONG ACTING METHYLPHENIDATES			
	DAYTRANA **FOCALIN XR*** methylin ER methylphenidate ER/CR/SA/SR tablets***			
	IMMEDIATE RELEASE METHYLPHENIDATES			
	dexmethylphenidate methylin tablets methylphenidate tablets			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (Generic is preferred if available. PLEASE CONTACT DHS FOR QUESTIONS)
MENTAL HEALTH continued	**SELECTIVE ALPHA-ADRENERGIC AGONIST**		To obtain the **non-preferred agent**, client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive Kapvay, clients must have completed a 14 day trial of clonidine IR with benefit in the previous 12 months.	**KAPVAY***
	clonidine			
	GUANFACINE AGENTS		To obtain the **non-preferred agent**, client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive guanfacine ER, clients in the previous 12 months must have: A) a trial and failure of a stimulant greater than or equal to a 14 day supply, or B) a trial and failure of Strattera greater than or equal to a 30 day supply, or C) a contraindication to ADHD medications (including stimulant and non-stimulant), or D) a diagnosis of a TIC disorder, **AND** E) a 14 day trial of guanfacine **with benefit**	guanfacine ER
	guanfacine			
	SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR		Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, or refractory depression (see refractory depression criteria below). Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 4. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Dosage limits apply: STRATTERA: 150mg/day	
		STRATTERA		
MIGRAINE	**TRIPTANS**		Trial and failure of two preferred agents will be required for approval of a non-preferred agent. Rizatriptan will be approved for clients between 6 and 17 years of age Quantity limits apply: naratriptan 1mg: 25 tabs/34 days naratriptan 2.5mg: 10 tabs/34 days RELPAX 20mg: 20 tabs/34 days RELPAX 40mg: 14 tabs/34 days sumatriptan vials: 2 vials/34 days sumatriptan nasal: 6 bottles/34 days sumatriptan 25mg: 41 tabs/34 days sumatriptan 50mg: 20 tabs/34 days sumatriptan 100mg: 10 tabs/34 days	almotriptan frovatriptan ONZETRA *(use preferred agent)* rizatriptan TREXIMET ZEMBRACE *(use preferred agent)* zolmitriptan
	naratriptan RELPAX sumatriptan			
MULTIPLE SCLEROSIS	**STEP 1 MS AGENTS**		Trial and failure of one injectable preferred agent will be required before approval can be given for the step 2 MS agent (Gilenya). Trial and failure of a two preferred agents (each from a separate class) will be required before approval can be given for a non-preferred agent. *Ocrevus will be approved for a diagnosis of primary progressive multiple sclerosis. For relapsing forms of multiple sclerosis, the requirements listed above will need to be followed For Tysabri, in addition to the above criteria, additional prior authorization criteria applies.	COPAXONE 40MG/ML *(use preferred agent)* EXTAVIA LEMTRADA OCREVUS* PLEGRIDY TECFIDERA TYSABRI (additional criteria applies) ZINBRYTA
	IMMUNOMODULATOR (GLATIRAMER INJECTION)			
	COPAXONE 20MG/ML			
	INTERFERON			
	AVONEX BETASERON REBIF			
	PYRIMIDINE SYNTHESIS INHIBITOR			
	AUBAGIO			
	STEP 2 MS AGENTS			
		GILENYA		
NEUROPATHIC PAIN	**TRICYCLIC ANTIDEPRESSANTS**		For the diagnosis of neuropathic pain, trial and failure of a tricyclic antidepressant greater than or equal to a 12 week supply AND trial and failure of gabapentin at a dose of 3600mg per day for greater than or equal to a 12 week supply in the last 12 months will be required before approval can be given for a non-preferred agent.	duloxetine LYRICA
		amitriptyline desipramine imipramine nortriptyline		
	GABAPENTIN			
		gabapentin		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES PRIOR AUTHORIZATION REQUIRED PLEASE CONTACT DHS FOR QUESTIONS
OPHTHALMICS	**OP. -ANTI-ALLERGICS**		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Emadine, Alomide, and Alocril will be approved for pregnancy. Alomide will be approved for children under the age of 3.	ALAMAST ALOCRIL ALOMIDE ALREX azelastine BEPREVE EMADINE epinastine ketotifen LASTACAFT PATADAY
	cromolyn olopatadine PAZEO			
	OP. -ANTIBIOTICS- QUINOLONES		Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent. Azasite will be approved for pregnancy.	AZASITE BESIVANCE gatifloxacin IQUIX levofloxacin ZYMAR
	ciprofloxacin ofloxacin MOXEZA VIGAMOX			
	OP. -ANTI-INFLAMMATORY		Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACULAR/LS/PF *(use preferred)* ACUVAIL bromfenac 0.9% BROMSITE NEVENAC PROLENSA
	flurbiprofen diclofenac DUREZOL LOTEMAX ketorolac ILEVRO			
	OP. -BETA-BLOCKERS		Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPTIC S ISTALOL
	betaxolol carteolol levobunolol metipranolol timolol			
	OP. -CARBONIC ANHYDRASE INHIBITOR		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	AZOPT
	dorzolamide			
	OP. - COMBO PRODUCTS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	
	COMBIGAN dorzolamide/timolol SIMBRINZA			
	OP. - DRY EYE AGENTS			
	RESTASIS XIIDRA			
	OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	bimatoprost LUMIGAN 0.1% ZIOPTAN
	latanoprost TRAVATAN Z			
	OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ALPHAGAN P 0.1% brimonidine 0.15% (BRAND IS PREFERRED)
	ALPHAGAN P 0.15%* brimonidine 0.2%			
OSTEOPOROSIS	**BISPHOSPHONATES**		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing.	risedronate ATELVIA FOSAMAX-D ibandronate TYMLOS
	alendronate			
	NASAL CALCITONIN			
	calcitonin-salmon fortical			
OVERACTIVE BLADDER	**OVERACTIVE BLADDER AGENTS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	darifenacin GELNIQUE GEL 10% MYRBETRIQ OXYTROL DIS SANCTURA XR tolterodine/ER trospium
	oxybutynin /ER TOVIAZ VESICARE			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES PREFERRED AGENTS MAY BE CHANGED PLEASE CONTACT OHS FOR QUESTIONS
PAIN	**LONG-ACTING C-IIs**		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. C-IIIs and C-IVs that are not included on the PDL and are available without prior authorization with the exception of Butrans (generic substitution is mandatory). Concurrent use of a narcotic and benzodiazepine will require prior authorization Fentanyl patches will require a prior authorization unless a client has a cancer diagnosis or previous treatment of at least a 10 day supply within the last 45 days **Butrans requires a trial of morphine sulfate ER or low dose trial of fentanyl patch. ***Nucynta ER will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics. ****In addition to above criteria, Embeda requires a diagnosis of drug/substance abuse. Belbuca: 1.2mg/day (1200mcg/day) Butrans: 20mcg, 1 strength at a time, 1 patch every 7 days Fentanyl: 50mcg, 1 strength at a time, 1 patch every 3 days Hysingla ER: 120mg/day Hydromorphone ER: 30mg/day Morphabond: 120mg/day Morphine ER: 120mg/day Methadone: Limited to 3 tablets per day Nucynta ER: 327mg/day Oxycontin: 80mg/day Oxymorphone ER: 40mg/day Xartemis XR: 80mg/day Xtampza ER: 80mg/day Zohydro ER: 120mg/day Clients will be limited to one long-acting narcotic at a time	AVINZA BELBUCA BUTRANS** EMBEDA**** fentanyl patch 37.5, 62.5, 87.5mg hydromorphone ER HYSINGLA ER *(additional criteria applies)* KADIAN 200mg *(use preferred agent)* METHADONE MORPHABOND morphine sulfate ER capsules *(use preferred)* NUCYNTA ER*** oxymorphone ER OXYCONTIN XARTEMIS XR *(additional criteria applies)* XTAMPZA ER *(additional criteria applies)* ZOHYDRO ER *(additional criteria applies)*
	fentanyl patch 12.5, 25, 50, 75, and morphine sulfate ER tablets			
	SHORT-ACTING C-IIs		Trial and failure of three (3) preferred agents greater than or equal to a 6 day supply in the last 90 days will be required before approval can be given for a non-preferred agent. *Nucynta will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics. Concurrent use of a narcotic and benzodiazepine will require prior authorization All short-acting narcotics, after 42 days of consecutive use of any combination of short-acting narcotics, will be limited to **4 tablets** per day (liquids have specific dosing limits per medication - please refer to dosage limitation chart at www.wymedicaid.org) Clients will be limited to one short-acting narcotic at a time	levorphanol NUCYNTA* oxymorphone oxycodone/IBU
	codeine sulfate hydrocodone/APAP hydrocodone/IBU hydromorphone LORTAB ELIXIR 10-300MG meperidine morphine sulfate oxycodone oxycodone/APAP oxycodone/ASA			
	C-III/C-V AGENTS		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Quantity and dosage limits apply (max 8 tabs/day). **Butrans will require a 14 day trial and failure of tramadol IR and a 14 day trial and failure of tramadol ER prior to approval	BUTRANS** RYBIX ODT tramadol/apap tramadol ER capsules tramadol ER tablets
	tramadol			
PHOSPHATE BINDERS	**PHOSPHATE BINDERS**		Prior authorization required for non-preferred agents.	AURYXIA FOSRENOL sevelamer VELPHORO
	calcium acetate PHOSLYRA RENAGEL			
PROSTATE	**5-ALPHA-REDUCTASE INHIBITORS**		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	dutasteride dutasteride/tamsulosin *(use separate agents)*
	finasteride			
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin dutasteride/tamsulosin *(use separate agents)* RAPAFLO
	doxazosin tamsulosin terazosin			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES Prescriber's authority required PLEASE CONTACT QHS FOR QUESTIONS
PULMONARY ANTIHYPERTENSIVES	**5-ALPHA-REDUCTASE INHIBITORS**	ADCIRCA REVATIO SUSPENSION sildenafil (Revatio A/B rated generic)	Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
	ENDOTHELIN RECEPTOR ANTAGONISTS	LETAIRIS TRACLEER	Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	OPSUMIT *(use preferred agent)*
	PROSTACYCLINE VASODILATORS	ORENITRAM	Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
	PROSTACYCLINE RECEPTOR AGONIST		Prior authorization required.	UPTRAVI *(use preferred pulmonary HTN agent)*
RESTLESS LEG SYNDROME	**RESTLESS LEG SYNDROME**	gabapentin pramipexole ropinirole	Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent. *Neupro will be approved for clients with difficulty swallowing or for clients with a diagnosis of Parkinson's Disease.	HORIZANT NEUPRO*
SKELETAL MUSCLE RELAXANTS	**MUSCLE RELAXANTS** baclofen cyclobenzaprine tizanidine tablets		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months, along with a medical diagnosis of muscle spasticity will be required before approval can be given for a non-preferred agent. Cyclobenzaprine will require a prior authorization for clients concurrently taking a tricylic antidepressant.	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine tizanidine capsules *(use preferred agent)* Carisoprodol is limited to 84 tabs/365 days
ULCERATIVE COLITIS	**IMMUNOMODULATORS**	HUMIRA	Client must have diagnosis of UC prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of UC and a 56-day trial and failure of the preferred agent.	REMICADE
UVEITIS	**IMMUNOMODULATORS**	HUMIRA	Client must have diagnosis of non-infectious intermediate, posterior, and panuveitis in adult patients	